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COMT Val108/158Met genotype counts and frequencies in male and female
control subjects, and patients with schizophrenia or alcohol dependence, further
subdivided according to the smoking status into smokers and non-smokers.
COMT Val108/158Met genotype
Male subjects Female subjects
Met/Met Val/Met Val/Val Met/Met Val/Met Val/Val
N (%) N (%) N (%) N (%) N (%) N (%)
Healthy control
smokers
56 93 69a 15 39 15
(25.7) (42.7) (31.6) (22.4) (55.2) (22.4)
Healthy control
non-smokers
108 267 111 78 134 73
(22.2) (54.9) (22.9) (28.6) (45) (26.4)
Smokers with
schizophrenia
104 185 93 29 58 36
(27.2) (48.4) (24.4) (23.6) (47.1) (29.3)
Non-smokers
with
schizophrenia
47 87 42 31 68 48
(26.7) (49.4) (23.9) (21.1) (46.3) (32.6)
Smokers with
alcoholism
75 154 72 23 30 15
(24.9) (51.2) (23.9) (33.8) (44.1) (22.1)
Non-smokers
with
alcoholism
52 103 37 14 27 14
(27.1) (53.6) (19.3) (25.4) (49.2) (25.4)
COMT: catechol-O-methyl transferase; Met: methonine; Val: valine; N: genotype
count.
aP¼0.008 vs. healthy male non-smokers (w2 test).The lack of association between catechol-O-methyl-transferase
Val108/158Met polymorphism and smoking in schizophrenia
and alcohol dependence
To the Editors
Patients with schizophrenia and alcohol dependence are often
smokers. There are inconsistencies across the literature on the
relationship between the functional catechol-O-methyl-transferase
(COMT) Val108/158Met polymorphism and smoking and/or nicotine
dependence (Redden et al., 2005; Tammimaki and Mannisto, 2010).
The study elucidated the association between the COMT
Val108/158Met polymorphism and smoking in 828 ethnically
homogeneous non-related Caucasian patients with schizophrenia
(40.3712.6 years old), 616 patients with alcohol dependence
(49.7710.2 years old), diagnosed with the Structured Clinical
Interview for DSM-IV, and in 1058 healthy control subjects
(40.5715.3 years old). The COMT Val108/158Met polymorphism
was genotyped using a Taqman-based allele-specific polymerase
chain reaction assay (Applied Biosystems, Foster City, CA, USA).
COMT genotypes in the studied groups were in Hardy–
Weinberg equilibrium. The present smoking status differed sig-
nificantly (w2¼327.71; Po0.001) between the studied groups,
since male patients with schizophrenia smoked more frequently,
while healthy control women smoked less frequently than other
subjects. The stepwise logistic regression (odds ratio (OR)¼1.56,
95% confidence interval (CI)¼1.10–2.23, P¼0.014) and the w2 test
(Table 1) revealed that the COMT Val/Val genotype was signifi-
cantly associated with smoking in healthy male subjects, since
carriers of one (w2¼5.686; P¼0.017) or two (w2¼9.783; P¼0.008)
Val alleles were more frequently current smokers.
The significant association between smoking, age and gender,
with no interaction between smoking and COMT Val108/158Met
variants in patients with schizophrenia and alcohol dependence,
might be explained by the different effects of nicotine on
social and interpersonal factors in psychiatric versus healthy
subjects, or by the different interactions between dopamine
activity and nicotine in the regions involved in the regulation of
the reward pathways in healthy opposed to subjects with schizo-
phrenia and alcohol dependence. Although the hypothesis of the
study was that COMT Val108/158Met genotypes would be sig-
nificantly associated with smoking in schizophrenia and alcohol
dependence, our study, with a sufficiently large sample size
(N¼2502) and power (higher than 0.800), with subjects matched
for the first time the lack of a significant association between
smoking and the COMT Val108/158Met polymorphism in schizo-
phrenia, and confirmed no association between smoking and the
COMT Val108/158Met polymorphism in alcoholism (Foroud et al.,
2007). In line with previous results obtained in smaller groups81/$ - see front matter & 2012 Elsevier Ireland Ltd. All rights reserved.
x.doi.org/10.1016/j.psychres.2012.08.001(Nedic et al., 2010), the COMT Val108/158Met polymorphism was
significantly associated with smoking in healthy male subjects,
due to the over-representation of the Val/Val genotype in healthy
male current smokers.References
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